Michael Steven Perry
Independent DirectorDr. Michael Steven Perry, also known as Mike, D.V.M., Ph.D. & FACVPT, was Non-Executive Director of Arovella Therapeutics Limited from April 28, 2026 until May 4, 2026. Dr. Perry is Chairman of Xeno Transplants Corporation. Dr. Perry joined the Xeno Transplants Corporation on May 03, 2007. Dr. Perry is Independent Director of Arrowhead Pharmaceuticals, Inc. from 2011 and served as its Independent Lead Director. Dr. Perry joined the Arrowhead Pharmaceuticals, Inc. on December 19, 2011. Dr. Perry is Venture Partner of Bioscience Managers Pty Ltd. Dr. Perry was Managing Director of Bioscience Managers Pty Ltd. Dr. Perry was Director & Operating Partner of Bioscience Managers Pty Ltd. Dr. Perry was Member of Scientific Advisory Board of 7 Hills Pharma Inc. until June 2026. Dr. Perry was Chairman of the Board of 7 Hills Pharma Inc. from July 2021. Dr. Perry was Director of Regulatory Affairs of Schering-Plough Corporation. Dr. Perry was Vice President and Senior Global Program Head of Stem Cell Therapy of Novartis Pharmaceuticals Corporation. Dr. Perry was President and Chief Medical Officer of Poniard Pharmaceuticals, Inc. Dr. Perry was employed at Poniard Pharmaceuticals, Inc. from February 05, 2010 to December 06, 2013. Dr. Perry was Non-Executive Director of AVITA Medical, Inc. from 2022 to December 13, 2022. Dr. Perry was President & Executive Director of AVITA Medical, Inc. from September 29, 2022 to September 2022. Dr. Perry was CEO, President & Executive Director of AVITA Medical, Inc. until September 29, 2022. Dr. Perry was CEO & Executive Director of AVITA Medical, Inc. from June 01, 2017. Dr. Perry was employed at AVITA Medical, Inc. from February 04, 2013 to December 12, 2022. Dr. Perry was Chief Development Officer of VIA Pharmaceuticals, Inc. Dr. Perry was Independent Director of AmpliPhi Biosciences Corporation from November 2005. Dr. Perry joined the AmpliPhi Biosciences Corporation in November 2005. Dr. Perry was Chairman of Icon Development Inc. Dr. Perry joined the Icon Development Inc on May 03, 2007. Dr. Perry was President, Cell & Gene Therapy of Genetic Therapy Inc. Dr. Perry was Chief Executive Officer, President and Director of Certara Strategic Consulting. Dr. Perry was employed at Certara Strategic Consulting from February 2002 to February 10, 2003. Dr. Perry was Director of BioTransplant Incorporated from January 1999. Dr. Perry joined the BioTransplant Incorporated in January 1999. Dr. Perry was President, Cell & Gene Therapy of SyStemix, Inc. Dr. Perry was employed at SyStemix, Inc. until December 06, 2013. Dr. Perry was Independent Director of Gamida Cell Ltd. from May 2017 to May 20, 2021. Dr. Perry was employed at Gamida Cell Ltd. from May 2017 to May 20, 2021. Dr. Perry was Director of Arriva Pharmaceuticals, Inc. Dr. Perry was employed at Arriva Pharmaceuticals, Inc. until June 01, 2014. Dr. Perry was Director of Armata Pharmaceuticals, Inc. from 2019 to February 12, 2020. Dr. Perry was employed at Armata Pharmaceuticals, Inc. until February 12, 2020. Dr. Perry was Venture Partner of Bay City Capital LLC. Dr. Perry was employed at Bay City Capital LLC from 2005 to June 01, 2014. Dr. Michael Perry is passionate about supporting innovative healthcare companies develop and commercialize products and technologies intended to address unmet medical needs in patients. He is inspired to invest in and recurrently assume leadership roles in companies employing cutting edge medical technologies including regenerative medicines such as cell, gene and tissue therapies. Currently, he serves on the boards of Armata Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Avita Medical Ltd, Gamida Cell Ltd and previously served on American Xeno Inc, Arriva Therapeutics, California Healthcare Institute, Genetic Therapy, Inc, Itamar Medical, Keck Graduate Institute, PharSight Corp., SyStemix Inc., Targeted Genetics, Xenotransplant, Inc. He concurrently serves as Adjunct Professor at the Gates Center for Regenerative Medicine at the Anschutz Medical Campus of University of Colorado, Denver and he Chairs the External Advisory Board for Translational Medicine at the Houston Methodist Research Institute. Mike has several years of experience in the healthcare industry ranging from a variety of executive roles in top tier large pharma companies, to serving as CEO for multiple Biotech/Medtech companies and operating for as a venture partner in a US-based healthcare VC fund. Dr. Perry has Ph.D. in Bio Medical Engineering, Biomedical Sciences & Pharmacology from University Of Guelph from 1982 to 1986, B.S. in Engineering & Physics from University Of Guelph from 1978 to 1982, D.D. in Surgery & Veterinary Medicine from University Of Guelph from 1982 to 1986. Dr. Perry attended Harvard Business School with specialty in International Management in 1999.
公司职务
- 公司名称Arrowhead Pharmaceuticals, Inc.股票代码ARWR职务Independent Director共事同僚
- CRChristopher R. AnzaloneChairman, CEO & President
- DJDaniel J. ApelChief Financial Officer
- POPatrick O'BrienCOO & Secretary
- JCJames C. HamiltonChief Medical Officer and Head of R&D
- MMMark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & Calando
- RGRobert G. GishChairman of Hepatitis B Clinical Advisory Board
- WDWilliam D. WaddillIndependent Lead Director
